Screener
Castle Biosciences CSTL Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| NET REVENUES | $83,679 | $87,988 |
| OPERATING EXPENSES | ||
| Cost of sales (exclusive of amortization of acquired intangible assets) | 20,533 | 16,383 |
| Research and development | 14,428 | 12,588 |
| Selling, general and administrative | 64,899 | 58,620 |
| Amortization of acquired intangible assets | 2,226 | 28,325 |
| Total operating expenses, net | 102,086 | 115,916 |
| Operating loss | (18,407) | (27,928) |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's total revenue?
- Castle Biosciences (CSTL) reported total revenue of $83.68M in Q1 2026.
- How has Castle Biosciences's total revenue changed year-over-year?
- Castle Biosciences's total revenue decreased by 4.9% year-over-year, from $87.99M to $83.68M.
- What is the long-term trend for Castle Biosciences's total revenue?
- Over 4 years (2021 to 2025), Castle Biosciences's total revenue has grown at a 38.3% compound annual growth rate (CAGR), from $94.09M to $344.23M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Castle Biosciences's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude